SALT
LAKE CITY, Sept. 7, 2023 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or
"Co-Dx"), a molecular diagnostics company with a unique, patented
platform for the development of molecular diagnostic tests,
announced today that Co-Diagnostics will be presenting at the H.C.
Wainwright & Co. 25th Annual Global Investment
Conference, being held virtually and in-person on September 11-13 in New
York City, New York.
Dwight Egan, Company CEO, will be
conducting a presentation discussing Company progress on its
forthcoming Co-Dx PCR Home™ platform. The presentation can be
accessed by clicking here or through the Events and Webcasts
section of the Co-Diagnostics website on September 12, 2023 at 2:30
PM Eastern Time, for institutional investors and industry
professionals who have registered for the event.
The Company will also be participating in one-on-one meetings,
which can be arranged with H.C. Wainwright representatives.
The Co-Dx PCR Home platform is subject to FDA review and is
not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests to locate genetic markers for use in industries other than
infectious disease and license the use of those tests to specific
customers.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-participate-in-the-hc-wainwright-25th-annual-global-investment-conference-on-september-11-13-2023-301920689.html
SOURCE Co-Diagnostics